HST Global Enters into Letter of Intent to Acquire Treatment Facility

HAMPTON, Va.--()--HST Global, Inc. (OTCBB:HSTC) today announced it is reaching across the globe to insure that immunotherapy and alternative treatments and solutions are available to all communities. Alternative therapies are achieving extraordinary degrees of success, as demonstrated by companies such as Dendreon Corporation (NASDAQ:DNDN) whose immunotherapy prostate-cancer drug Provenge was found to extend survival rates. HST anticipates completing the acquisition of the center in the next ninety (90) days.

Ron Howell, President and CEO of HST Global, Inc. stated, “HST is excited to have completed the initial documentation necessary to initiate the acquisition of our first Health and Wellness Center. As stated previously, the company intends to open three (3) to five (5) centers worldwide during 2009. This acquisition will allow the company to provide alternative health care options for those who are suffering from late stage cancer.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com